Which diabetes drug is better for heart failure? new study compares tirzepatide and semaglutide
NCT ID NCT06914141
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at over 28,000 people with type 2 diabetes and a type of heart failure called HFpEF. Researchers compared two drugs, tirzepatide and semaglutide, to see which one better reduces the risk of death or hospitalization for heart failure. The study used real-world data from insurance claims to mimic a clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide and semaglutide (drugs for diabetes and weight loss)
What this could lead to
If one drug proves clearly better, it could guide doctors to choose the most effective treatment for heart failure patients with diabetes.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States